Extracellular Vesicle Therapy for Type 1 Diabetes
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 1,29 MB, PDF-dokument
Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 865782 |
Tidsskrift | Frontiers in Immunology |
Vol/bind | 13 |
ISSN | 1664-3224 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
The Lundbeck foundation grant R303-2018-3148 supported this work.
Publisher Copyright:
Copyright © 2022 Soltani, Mansouri, Emami Aleagha, Moasefi, Yavari, Shakouri, Notararigo, Shojaeian, Pociot and Yarani.
ID: 305713545